Table 3.
Summary of the included COVID-19 cross-sectional studies.
| Study | Country Study Period | Quality Assessment | Participant Characteristics | Other Audio-Vestibular Manifestations | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Publicat-ion Date | Participants (n = 8913) | Gender | Age in Years (Mean, Median, and Range) | Tinnitus | Hearing Loss | Vestibular Impairments | Taste Disorders | Smell Disorders | |||
| Daikhes et al. [32] | Russia 4/2020–6/2020 |
Poor | 20/07/2020 | n = 108 (including n = 30 as a control) | Not provided | NA, 20–50, NA | n = 14 (17%) | X | |||
| Davis et al. [33] | International (39 countries) 9/6/2020–11/25/2020 |
Fair | 26/12/2020 | n = 3762 | M = 19.1% F = 78.9% Other = 2% | NA, NA,30–60 | n = 1280 (34%) | X | X | X | X |
| Elibol [34] | Turkey 3/25/2020–4/25/2020 |
Fair | 01/09/2020 | n = 155 | M = 41.3% F = 58.7% | 36.3 (8.1), NA, 18–72 | n = 2 (1.3%) | X | X | X | |
| Freni et al. [35] | Italy Not stated |
Fair | 18/06/2020 | n = 50 (including n = 20 as a control) | M = 60% F = 40% | 37.7 (17.9), NA, 18–65 | n = 10 (20%) | X | X | X | |
| Iqbal et al. [36] | Pakistan 9/2020–12/2020 |
Good | 02/02/2021 | n = 158 | M = 44.9% F = 55.1% | 32.1 (12.42), NA, 19–80 | n = 30 (19%) | X | X | ||
| Kamal et al. [37] | Egypt Not stated |
Fair | 29/09/2020 | n = 287 | M = 35.9% F = 64.1% | 32.3 (8.5), NA, 20–60 | n = 48 (17%) | ||||
| Karadaş et al. [38] | Turkey | Fair | 25/06/2020 | n = 239 | M = 55.6% F= 44.4% | 46.46 (15.41), 19–88 | n = 5 (2.1%) | X | X | X | X |
| Klopfenstein et al. [39] | France 3/1/2020–3/14/2020 |
Fair | 04/08/2020 | n = 70 | M = 33% F = 67% | 47 (16), NA, NA | n = 7 (10%) | X | X | X | |
| Özçelik Korkmaz et al. [40] | Turkey 4/2020–5/2020 |
Fair | 03/10/2020 | n = 116 | M = 50% F = 50% | 57.4 (14.32), NA, 19–83 | n = 13 (11%) | X | X | X | X |
| Lechien et al. [41] | Europe 3/22/2020–4/10/2020 |
Fair | 30/04/2020 | n = 1420 | M = 32.3% F = 67.7% | 39.17 (12.09), 37, NA | n = 5 (0.3%) | X | X | ||
| Liang et al. [42] | China 3/16/2020–4/12/2020 |
Fair | 24/06/2020 | n = 86 | M = 51.2% F = 48.8% | NA, 25.5, 6–57 | n = 3 (3.5%) | X | X | ||
| Micarelli et al. [43] | Italy 3/23/2020–3/30/2020 |
Fair | 20-Oct | n = 1380 | M = 39.3% F = 60.6% | NA, 23–72, NA | n = 144 (10%) | X | X | X | |
| Munro et al. [44] | UK Not stated |
Fair | 31/07/2020 | n = 121 | M = 87.5% F = 12.5% (of those with a change in tinnitus/hearing) | NA, 64, 44–82 | n = 8 (7%) | X | |||
| Savtale et al. [45] | India 10/1/2020–10/15/2020 |
Fair | 08/02/2021 | n= 180 | M= 33.4% F= 66.6% | 37.8 (12.5), NA, 18–65 | n = 120 (67%) | X | X | X | |
| Swain andPani [46] | India 3/2020–8/2020 |
Fair | 03/02/2021 | n = 472 | M = 64.3% F = 35.7% | 28.2, NA, 16–52 | n = 9 (2%) | X | X | X | |
| Viola et al. [47] | Italy 5/5/2020–6/10/2020 |
Fair | 23/10/2020 | n = 185 | M = 53.5% F = 46.5% | 52.15 (13), 53, 19–81 | n = 43 (23%) | X | |||
| Zayet et al. [48] | UK (France) 2/26/2020–3/14/2020 |
Fair | 16/06/2020 | n = 124, COVID group: n = 70; Influenza group: n = 54 | Overall group: M = 31% F = 69% COVID only group: M = 41.4% F = 58.6% | 59(13), NA, 19–98 | n = 7 (6%) out of the COVID only group | X | X | X | |